| |
 |
This is the category page. Below are all of the research programs that are associated with it
- Kidney Tumor in Children -
COG #AREN0533: TREATMENT OF NEWLY DIAGNOSED HIGHER RISK FAVORABLE HISTOLOGY WILMS TUMOR
(1_20080707_118)
This is associated with a previously approved study AREN0532. This study is for participants that have been on AREN0532 that have Stage III disease and are found to have loss of heterozygosity at chromosome 1p and 16q, which makes them no longer eligible for AREN0532. Participants can be transferred to this study and will be placed on regimen DD4A or regimen M depending on stage of disease. Participants will receive FDA approved drugs.
- Prostate Cancer -
INVESTIGATION OF TUMOR BURDEN AND QUALITY OF LIFE ISSUES IN PATIENTS TREATED FOR PROSTATE CANCER FOR USE IN GUIDING PATIENTS IN THEIR THERAPY DECISION MAKING PROCESS (Investigator Initiated Protocol)(1_20071002_118)
Participants will be interviewed in a group setting with no more than 10 others. This is commonly referred to as a focus group. The focus group will take about 90 minutes total. Participation in this research study is terminated at the conclusion of the focus group. During the focus group meeting questions will be asked about health history, current feelings, and particular lifestyle changes.
- Prostate Cancer -
SWOG S0421: PHASE III STUDY OF DOCETAXEL AND ATRASENTAN VERSUS DOCETAXEL AND PLACEBO FOR PATIENTS WITH ADVANCED HORMONE REFRACTORY PROSTATE CANCER
(2_20081104_118)
This is a Phase III study for patients with advanced prostate cancer. Participants will be randomly assigned to one of two treatment arm. One arm will receive docetaxel over 1 hour on day 1 of each 21 day cycle and prednisone and placebo, once a day; the other arm will receive docetaxel over 1 hour on day 1 of each 21 day cycle and prednisone and study drug, atrasentan, once a day. Participants will continue on this regimen for 12 cycles (36 weeks). If there has been no progression of disease the participant may continue on the study for a maximum of 52 weeks or until disease progression. Participants will be followed for 3 years.
- Prostate Cancer, Metastatic:
CALGB: C70604: A RANDOMIZED, PHASE III STUDY OF STANDARD DOSING VERSUS LONGER DOSING INTERVAL OF ZOLEDRONIC ACID IN METASTATIC CANCER
(2_20090604_118)
This is a study for patients with metastatic breast, prostate or multiple myeloma to bone. There are 2 arms to this study; Arm 1 is considered standard treatment and participants will receive Zoledronic acid IV over 15 minutes. This course will repeat every 4 weeks for up to 2 years or until disease progression or unacceptable side effects. Arm 2 is the considered the experimental treatment; participants will receive Zoledronic acid IV over 15 minutes; course repeats every 12 weeks for up to 2 years if no disease progression or unacceptable side effects. Participants will be instructed to take calcium and Vitamin D daily.
- Study Closed to Accrual: Kidney Tumor - ECOG #E2804: THE BEST TRIAL: A RANDOMIZED PHASE II STUDY OF VEGF, FAF KINASE, AND MTOR COMBINATION TARGETED THERAPY (CTT) WITH BEVACIZUMAB, SORAFENIB AND TEMSIROLIUMS IN ADVANCED RENAL CELL CARCINOMA (1_20071106_118)
There are four arms to this study. You will be randomly assigned to one of the study arms. Arm A will receive bevacizumab alone; Arm B will receive bevacizumab and temsirolimus; Arm C will receive bevacizumab and sorafenib; and Arm D will receive Temsirolimus and sorafenib. Blood tests will be done either every week or every other week depending on the treatment you are receiving. You may also be asked to have CT scans or MRI and Urinalysis test. You will be asked to continue with the research arm until your cancer begins to get worse. The researchers would like to keep track of your medical condition for 5 years following completion of the study. One cycle is equal to 28 days.
|
|
